Form D · Other
VIN-9 Nob Hill Therapeutics, LLC
Fayetteville, AR · CIK 0001787935
Offering snapshot reported Sep 12, 2019 · SEC filing
- Reported sold
- $65K Offering amount: $500K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Aug 26, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 12, 2019 | Initial | $65,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-348614
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Sep 12, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Calvin Goforth | Director, Executive |
| Mark Wagstaff | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
535 W. Research Center Blvd Ste 135
Fayetteville, AR, 72701
Fayetteville, AR, 72701